| Literature DB >> 22016603 |
Long Yi1, Xin Jin, Chun-Ye Chen, Yu-Jie Fu, Ting Zhang, Hui Chang, Yong Zhou, Jun-Dong Zhu, Qian-Yong Zhang, Man-Tian Mi.
Abstract
Vascular endothelial dysfunction induced by oxidative stress has been demonstrated to be the initiation step of atherosclerosis (AS), and flavonoids may play an important role in AS prevention and therapy. Twenty-three flavonoids categorized into flavones, flavonols, isoflavones, and flavanones, all with 4-oxo-pyronenucleus, were examined for what structural characteristics are required for the inhibitory effects on endothelial dysfunction induced by oxidized low-density lipoprotein (oxLDL). Human vascular endothelial cells EA.hy926 were pretreated with different 4-oxo-flavonoids for 2 hs, and then exposed to oxLDL for another 24 hs. Cell viability and the level of malondialdehyde (MDA), nitric oxide (NO) and soluble intercellular adhesion molecule-1 (sICAM-1) were measured, respectively. Then, correlation analysis and paired comparison were used to analyze the structure-activity relationships. Significant correlations were observed between the number of -OH moieties in total or in B-ring and the inhibitory effectson endothelial dysfunction. Furthermore, 3',4'-ortho-dihydroxyl on B-ring, 3-hydroxyl on C-ring and 2,3-double bondwere correlated closely to the inhibitory effects of flavonolson cell viability decrease and lipid peroxidation. 5,7-meta-dihydroxyl group on A-ring was crucial for the anti-inflammatory effects of flavones and isoflavones in endothelial cells. Moreover, the substituted position of B-ring on C3 rather than C2 was important for NO release. Additionally, hydroxylation at C6 position significantly attenuated the inhibitory effects of 4-oxo-flavonoids on endothelial dysfunction. Our findings indicated that the effective agents in inhibiting endothelial dysfunction include myricetin, quercetin, luteolin, apigenin, genistein and daidzein. Our work might provide some evidence for AS prevention and a strategy for the design of novel AS preventive agents.Entities:
Mesh:
Substances:
Year: 2011 PMID: 22016603 PMCID: PMC3189727 DOI: 10.3390/ijms12095471
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1The classification and structure of the flavonoids: (a) flavan nucleus; (b) 4-oxo-flavonoid nucleus; (c) anthocyanidins; (d) flavones; (e) flavonols; (f) flavanones and (g) isoflavones.
Molecular characteristics of 23 4-oxo-flavonoids tested in our study.
| No. | Chemicals | Source | B-ring
| C-ring
| A-ring
| 2,3-double bond | The number of −OH
| |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| C2′ | C3′ | C4′ | C5′ | C6′ | C2 | C3 | C5 | C6 | C7 | C8 | In total | A-ring | B-ring | C-ring | ||||
| 1 | flavone | Sigma | −H | −H | −H | −H | −H | B-ring | −H | −H | −H | −H | −H | √ | 0 | 0 | 0 | 0 |
| 2 | chrysin | Sigma | −H | −H | −H | −H | −H | B-ring | −H | −OH | −H | −OH | −H | √ | 2 | 2 | 0 | 0 |
| 3 | apigenin | Sigma | −H | −H | −OH | −H | −H | B-ring | −H | −OH | −H | −OH | −H | √ | 3 | 2 | 1 | 0 |
| 4 | luteolin | Sigma | −H | −OH | −OH | −H | −H | B-ring | −H | −OH | −H | −OH | −H | √ | 4 | 2 | 2 | 0 |
| 5 | 6-hydroxyflavone | Sigma | −H | −H | −H | −H | −H | B-ring | −H | −H | −OH | −H | −H | √ | 1 | 1 | 0 | 0 |
| 6 | baicalein | Sigma | −H | −H | −H | −H | −H | B-ring | −H | −OH | −OH | −OH | −H | √ | 3 | 3 | 0 | 0 |
| 7 | 7-hydroxyflavone | Sigma | −H | −H | −H | −H | −H | B-ring | −H | −H | −H | −OH | −H | √ | 1 | 1 | 0 | 0 |
| 8 | genistein | Sigma | −H | −H | −OH | −H | −H | −H | B−ring | −OH | −H | −OH | −H | √ | 3 | 2 | 1 | 0 |
| 9 | daidzein | Sigma | −H | −H | −OH | −H | −H | −H | B−ring | −H | −H | −OH | −H | √ | 2 | 1 | 1 | 0 |
| 10 | hesperetin | Sigma | −H | −OH | −OCH3 | −H | −H | B-ring | −H | −OH | −H | −OH | −H | − | 3 | 2 | 1 | 0 |
| 11 | flavanone | Sigma | −H | −H | −H | −H | −H | B-ring | −H | −H | −H | −H | −H | − | 0 | 0 | 0 | 0 |
| 12 | naringenin | Sigma | −H | −H | −OH | −H | −H | B-ring | −H | −OH | −H | −OH | −H | − | 3 | 2 | 1 | 0 |
| 13 | 2′-hydroxyflavanone | Sigma | −OH | −H | −H | −H | −H | B-ring | −H | −H | −H | −H | −H | − | 1 | 0 | 1 | 0 |
| 14 | 4′-hydroxyflavanone | Sigma | −H | −H | −OH | −H | −H | B-ring | −H | −H | −H | −H | −H | − | 1 | 0 | 1 | 0 |
| 15 | galangin | Sigma | −H | −H | −H | −H | −H | B-ring | −OH | −OH | −H | −OH | −H | √ | 3 | 2 | 0 | 1 |
| 16 | morin | Sigma | −OH | −H | −OH | −H | −H | B-ring | −OH | −OH | −H | −OH | −H | √ | 5 | 2 | 2 | 1 |
| 17 | myricetin | Sigma | −H | −OH | −OH | −OH | −H | B-ring | −OH | −OH | −H | −OH | −H | √ | 6 | 2 | 3 | 1 |
| 18 | fisetin | Sigma | −H | −OH | −OH | −H | −H | B-ring | −OH | −H | −H | −OH | −H | √ | 4 | 1 | 2 | 1 |
| 19 | geraldol | Sigma | −H | −OCH3 | −OH | −H | −H | B-ring | −OH | −H | −H | −OH | −H | √ | 3 | 1 | 1 | 1 |
| 20 | quercetin | Sigma | −H | −OH | −OH | −H | −H | B-ring | −OH | −OH | −H | −OH | −H | √ | 5 | 2 | 2 | 1 |
| 21 | gossypin | Sigma | −H | −OH | −OH | −H | −H | B-ring | −OH | −OH | −H | −OH | O-glucoside | √ | 5 | 2 | 2 | 1 |
| 22 | 3,6-dihydroxyflavone | Sigma | −H | −H | −H | −H | −H | B-ring | −OH | −H | −OH | −H | −H | √ | 2 | 1 | 0 | 1 |
| 23 | 3,7-dihydroxyflavone | Sigma | −H | −H | −H | −H | −H | B-ring | −OH | −H | −H | −OH | −H | √ | 2 | 1 | 0 | 1 |
Effect of 4-oxo-flavonoids with different concentrations on oxLDL-induced endothelial viability. EA.hy926 cells were pretreated with different 4-oxo-flavonoids at a series of concentration (5, 10, 20, 40 and 80 μM) for 2 hs and exposed to oxLDL of 100 μg/mL for another 24 hs. The optical density was measured at 450 nm and the values were determined as the percentage of the control group.
| Groups | Cell viability (% of control)
| |||||
|---|---|---|---|---|---|---|
| 5 μM | 10 μM | 20 μM | 40 μM | 80 μM | ||
| Control | 100.00 | |||||
| 0.2% DMSO | 106.36 ± 10.32 | |||||
| 100 μg/mL oxLDL | 47.11± 5.19 | |||||
| flavone | 47.76 ± 4.77 | 48.27 ± 5.91 | 45.22 ± 5.50 | 45.88 ± 7.92 | 40.65 ± 6.53 | |
| chrysin | 48.08 ± 3.83 | 47.29 ± 8.56 | 53.98± 5.64 | 58.73 ± 4.16 | 45.12 ± 2.94 | |
| apigenin | 53.86 ± 2.89 | 50.67 ± 6.25 | 54.64± 8.36 | 48.73 ± 5.08 | 42.79 ± 5.35 | |
| luteolin | 55.96 ± 1.99 | 59.48 ± 6.32 | 61.04 ± 6.74 | 68.27 ± 8.22 | 76.44 ± 4.46 | |
| 6-hydroxyflavone | 46.99 ± 7.92 | 43.90 ± 4.19 | 40.60 ± 6.04 | 35.34 ± 6.59 | 29.51 ± 4.84 | |
| baicalein | 48.62 ± 2.28 | 50.25 ± 6.87 | 57.17± 6.38 | 65.81 ± 4.90 | 57.76 ± 5.51 | |
| 7-hydroxyflavone | 50.34 ± 3.31 | 49.12 ± 8.92 | 44.46 ± 9.43 | 40.47 ± 2.32 | 33.23 ± 3.36 | |
| genistein | 51.15 ± 2.72 | 46.53 ± 6.70 | 52.81± 4.68 | 56.03 ± 7.71 | 43.46 ± 4.65 | |
| daidzein | 47.88 ± 4.22 | 47.94 ± 8.29 | 46.85± 11.10 | 53.94 ± 6.72 | 35.38 ± 9.70 | |
| hesperetin | 49.72 ± 3.25 | 47.45 ± 3.03 | 57.32± 4.29 | 53.49 ± 2.89 | 45.89 ± 6.56 | |
| flavanone | 44.69 ± 5.27 | 48.48 ± 6.40 | 42.94± 4.56 | 38.20 ± 5.77 | 34.37 ± 3.31 | |
| naringenin | 49.47 ± 3.18 | 49.41 ± 7.63 | 54.10± 4.90 | 51.52 ± 6.26 | 40.41 ± 6.79 | |
| 2′-hydroxyflavanone | 49.21 ± 3.02 | 51.41 ± 6.40 | 44.29± 3.01 | 45.51 ± 11.98 | 41.70 ± 6.59 | |
| 4′-hydroxyflavanone | 51.64 ± 6.31 | 54.01 ± 5.54 | 49.50± 10.23 | 47.08 ± 3.38 | 43.23 ± 3.81 | |
| galangin | 52.15 ± 3.57 | 56.59 ± 3.56 | 62.29± 4.35 | 67.78 ± 5.69 | 68.56 ± 2.24 | |
| morin | 53.24 ± 3.51 | 54.00 ± 7.73 | 59.72± 3.85 | 65.37 ± 11.06 | 71.60 ± 4.45 | |
| myricetin | 53.07 ± 2.00 | 60.19 ± 5.12 | 68.41± 4.60 | 73.26 ± 3.61 | 82.58 ± 3.67 | |
| fisetin | 51.66 ± 3.97 | 58.92 ± 3.44 | 64.49± 8.1 | 71.22 ± 4.73 | 79.40 ± 5.55 | |
| geraldol | 49.35 ± 3.52 | 50.63 ± 7.49 | 45.57± 2.57 | 55.81 ± 2.60 | 40.24 ± 3.75 | |
| quercetin | 50.75 ± 2.13 | 59.49 ± 7.71 | 66.32± 6.4 | 73.63 ± 3.87 | 81.53 ± 6.18 | |
| gossypin | 48.99 ± 3.27 | 58.15 ± 3.34 | 65.31± 6.5 | 67.87 ± 4.50 | 78.78 ± 4.42 | |
| 3,6- dihydroxyflavone | 50.66 ± 6.11 | 50.11 ± 5.70 | 46.15± 7.99 | 39.38 ± 6.14 | 34.07 ± 4.31 | |
| 3,7- dihydroxyflavone | 45.74 ± 4.81 | 50.57 ± 7.01 | 42.87± 4.28 | 42.42 ± 4.67 | 39.12 ± 3.03 | |
P < 0.05,
P < 0.01, compared with control group;
P < 0.05,
P < 0.01, compared with oxLDL group.
Figure 2Effect of different 4-oxo-flavonoids of 40 μM on oxLDL-induced endothelial viability (A) and the level of MDA (B), NO (C) and sICAM-1 (D). EA.hy926 cells were pretreated with different 4-oxo-flavonoids of 40 μM, and exposed to oxLDL of 100 μg/mL for another 24 hs. Cell viability was measured by CCK-8 assay and the values were determined as the percentage of the control group. The level of MDA, NO, and sICAM-1 were determined by the corresponding detecting kits. All of the data are expressed as the means ± S.D. # P < 0.05, ## P < 0.01, compared with the control group; * P < 0.05, ** P < 0.01, compared with the oxLDL group.
Figure 3Correlation between the number of −OH groups of 4-oxo-flavonoids and the inhibitory effects on oxLDL-induced endothelial dysfunction. In the scatter plot, the X axis (horizontal axis) represents the number of −OH groups of flavonoids in total (A) or in B-ring; and (B), and the Y axis (vertical axis) represents the measurements of cell viability, MDA level NO level and sICAM-1 level, respectively. The overlay scatter plots represent 23 flavonoids in different experiments, respectively. Data were analyzed by Pearson’s correlation coefficient (r) and Fisher’s r to z (p) about 23 flavonoids. * P < 0.01.
Influence of changing substituents of 4-oxo-flavonoids on cell viability and the level of MDA, NO and sICAM-1 in oxLDL-induced EA.hy926 cells.
| Paired comparison
| Cell viability | MDA level | NO level | sICAM-1level | |||
|---|---|---|---|---|---|---|---|
| A | B | ||||||
| flavanone | 2′-hydroxyflavanone (2′-hydroxyl) | ↑ | ↓ | ↓ | ↑ | ||
| morin(2′,4′-dihydroxyl) | quercetin(3′,4′-dihydroxy) | ↑ | ↓ | ↑ | ↓ | ||
| geraldol (3′-methoxy, 4′-hydroxyl) | fistin (3′,4′-dihydroxyl) | ↑ | ↓ | ↑ | ↓ | ||
| apigenin (4′-hydroxyl) | luteolin (3′,4′-dihydroxyl) | ↑ | ↓ | ↓ | ↑ | ||
| 3,7-dihydroxyflavone | fistin (3′,4′-dihydroxyl) | ↑ | ↓ | ↑ | ↓ | ||
| flavanone | 4′-hydroxyflavanone (4′-hydroxyl) | ↑ | ↓ | ↑ | ↓ | ||
| chrysin | apigenin (4′-hydroxyl) | ↓ | ↓ | ↑ | ↓ | ||
| chrysin | luteolin (3′,4′-dihydroxyl) | ↑ | ↓ | ↑ | ↓ | ||
| galangin | morin (2′,4′-dihydroxyl) | ↓ | ↓ | ↓ | ↓ | ||
| galangin | myricetin (3′,4′,5′-trihydroxyl) | ↑ | ↓ | ↑ | ↓ | ||
| galangin | quercetin (3′,4′-dihydroxyl) | ↑ | ↓ | ↑ | ↓ | ||
| morin (2′,4′-dihydroxyl) | myricetin (3′,4′,5′-trihydroxyl) | ↑ | ↓ | ↑ | ↓ | ||
| morin (2′,4′-dihydroxyl) | quercetin (3′,4′-dihydroxyl) | ↑ | ↓ | ↑ | ↓ | ||
| 3,7-dihydroxyflavone | fistin (3′,4′-dihydroxyl) | ↑ | ↓ | ↑ | ↓ | ||
| 3,7-dihydroxyflavone | geraldol (3′-methoxyl, 4′-hydroxyl) | ↑ | ↓ | ↑ | ↓ | ||
| chrysin (2′,4′ - dihydroxyl) | luteolin (3′,4′-dihydroxyl) | ↑ | ↓ | ↑ | ↓ | ||
| quercetin (3′,4′-dihydroxyl) | myricetin (3′,4′,5′-trihydroxyl) | ↓ | ↓ | ↑ | ↑ | ||
| flavone | chrysin (5,7-dihydroxyl) | ↑ | ↓ | ↑ | ↓ | ||
| flavone | 6-hydroxyflavone (6-hydroxyl) | ↓ | ↑ | ↓ | ↑ | ||
| flavone | baicalein (5,6,7-trihydroxyl) | ↑ | ↑ | ↓ | ↓ | ||
| flavone | 7-hydroxyflavone (7-hydroxyl) | ↓ | ↓ | ↓ | ↑ | ||
| chrysin (5,7-dihydroxyl) | baicalein (5,6,7-trihydroxyl) | ↑ | ↑ | ↓ | ↑ | ||
| chrysin (5,7-dihydroxyl) | 7-hydroxyflavone (7-hydroxyl) | ↓ | ↓ | ↓ | ↑ | ||
| chrysin (5,7-dihydroxyl) | 6-hydroxyflavone (6-hydroxyl) | ↓ | ↑ | ↓ | ↑ | ||
| genistein | daidzein | ↓ | ↑ | ↓ | ↑ | ||
| fistin (7-hydroxyl) | quercetin(5,7-dihydroxyl) | ↑ | ↓ | ↑ | ↓ | ||
| fistin (7-hydroxyl) | gossypin (5,7-dihydroxyl, 8- | ↓ | ↓ | ↓ | ↑ | ||
| 6-hydroxyflavone (6- hydroxyl) | baicalein (5,6,7-trihydroxyl) | ↑ | ↓ | ↓ | ↓ | ||
| 6-hydroxyflavone (6- hydroxyl) | 7-hydroxyflavone (7-hydroxyl) | ↑ | ↓ | ↓ | ↓ | ||
| quercetin (5,7- dihydroxyl) | gossypin (5,7-dihydroxyl, 8- | ↓ | ↑ | ↓ | ↑ | ||
| 3,6-dihydroxyflavone (6-hydroxyl) | 3,7-dihydroxyflavone (7-hydroxyl) | ↑ | ↓ | ↑ | ↓ | ||
| chrysin | galangin (3-hydroxyl) | ↑ | ↓ | ↑ | ↓ | ||
| luteolin | quercetin(3-hydroxyl) | ↑ | ↓ | ↑ | ↓ | ||
| 7-hydroxyflavone (7- hydroxyl) | 3,7-dihydroxyflavone (3,7-dihydroxyl) | ↑ | ↑ | ↑ | ↑ | ||
| flavanone | flavone (2,3-double bond) | ↑ | ↓ | ↓ | ↓ | ||
| naringenin | apigenin (2,3-double bond) | ↓ | ↓ | ↑ | ↓ | ||
| apigenin (C2) | genistein (C3) | ↑ | ↓ | ↑ | ↑ | ||
P < 0.05,
P < 0.01, A vs. B in paired comparison; ↑: A < B; ↓: A > B.
Figure 4Effect of structural modificationsof 4-oxo-flavonoids on the inhibition of endothelial dysfunction by 3′,4′-ortho-dihydroxyl group (A1, A2 and A3), 5,7-meta-dihydroxyl group (B1, B2 and B3), 3-hydroxyl group (C1 and C2), 2,3-double bond (D1 and D2) and the substituted position of B-ring (E).
Figure 5Schematic representation of the chemical requirements of 4-oxo-flavonoids (flavones, flavanones, flavonols and isoflavones) for inhibition of endothelial dysfunction.